Asset Management One Co. Ltd. Grows Position in The Cooper Companies, Inc. $COO

Asset Management One Co. Ltd. lifted its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 3.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 88,313 shares of the medical device company’s stock after buying an additional 2,746 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Cooper Companies were worth $6,284,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Horizon Investments LLC raised its holdings in shares of Cooper Companies by 5.0% during the 1st quarter. Horizon Investments LLC now owns 2,859 shares of the medical device company’s stock valued at $241,000 after buying an additional 136 shares during the period. Axxcess Wealth Management LLC raised its holdings in shares of Cooper Companies by 1.9% during the 1st quarter. Axxcess Wealth Management LLC now owns 7,382 shares of the medical device company’s stock valued at $623,000 after buying an additional 140 shares during the period. Wealth Alliance LLC raised its holdings in shares of Cooper Companies by 5.5% during the 1st quarter. Wealth Alliance LLC now owns 4,059 shares of the medical device company’s stock valued at $342,000 after buying an additional 210 shares during the period. EverSource Wealth Advisors LLC raised its holdings in shares of Cooper Companies by 3.5% during the 1st quarter. EverSource Wealth Advisors LLC now owns 6,517 shares of the medical device company’s stock valued at $550,000 after buying an additional 220 shares during the period. Finally, Hardy Reed LLC raised its holdings in shares of Cooper Companies by 4.1% during the 2nd quarter. Hardy Reed LLC now owns 6,213 shares of the medical device company’s stock valued at $442,000 after buying an additional 244 shares during the period. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Brian G. Andrews bought 1,525 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The stock was bought at an average price of $65.68 per share, for a total transaction of $100,162.00. Following the transaction, the executive vice president owned 22,191 shares in the company, valued at $1,457,504.88. The trade was a 7.38% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Gerard H. Warner III bought 1,450 shares of the firm’s stock in a transaction dated Friday, September 5th. The stock was purchased at an average price of $69.23 per share, with a total value of $100,383.50. Following the transaction, the chief operating officer owned 18,319 shares in the company, valued at approximately $1,268,224.37. This represents a 8.60% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have acquired 17,975 shares of company stock worth $1,216,346. 1.98% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Mizuho dropped their target price on Cooper Companies from $105.00 to $90.00 and set an “outperform” rating on the stock in a report on Wednesday, July 16th. BNP Paribas Exane upgraded Cooper Companies from a “neutral” rating to an “outperform” rating and set a $92.00 price objective for the company in a research note on Tuesday, July 22nd. Piper Sandler lowered their price objective on Cooper Companies from $105.00 to $83.00 and set an “overweight” rating for the company in a research note on Thursday, August 28th. JPMorgan Chase & Co. lowered their price objective on Cooper Companies from $76.00 to $66.00 and set a “neutral” rating for the company in a research note on Thursday, August 28th. Finally, Barclays began coverage on Cooper Companies in a research note on Monday, October 13th. They set an “overweight” rating and a $85.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $84.77.

Cooper Companies Price Performance

Shares of COO opened at $71.75 on Wednesday. The firm has a market cap of $14.26 billion, a price-to-earnings ratio of 35.35, a PEG ratio of 1.91 and a beta of 1.02. The stock has a 50 day moving average of $69.61 and a 200-day moving average of $73.16. The company has a current ratio of 2.12, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29. The Cooper Companies, Inc. has a 52 week low of $61.78 and a 52 week high of $107.84.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Wednesday, August 27th. The medical device company reported $1.10 EPS for the quarter, topping the consensus estimate of $1.07 by $0.03. The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The business’s revenue was up 5.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.96 EPS. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies declared that its board has initiated a share buyback plan on Wednesday, September 17th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical device company to reacquire up to 15.4% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.